Literature DB >> 16403678

Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005.

Michael G Chez1, Mina Chang, Valerie Krasne, Carolyn Coughlan, Matthew Kominsky, Aaron Schwartz.   

Abstract

Autism spectrum disorders (ASDs) affect 1 in 166 births. Although electroencephalogram (EEG) abnormalities and clinical seizures may play a role in ASDs, the exact frequency of EEG abnormalities in an ASD population that has not had clinical seizures or prior abnormal EEGs is unknown. There is no current consensus on whether treatment of EEG abnormalities may influence development. This retrospective review of 24-hour ambulatory digital EEG data collected from 889 ASD patients presenting between 1996 and 2005 (with no known genetic conditions, brain malformations, prior medications, or clinical seizures) shows that 540 of 889 (60.7%) subjects had abnormal EEG epileptiform activity in sleep with no difference based on clinical regression. The most frequent sites of epileptiform abnormalities were localized over the right temporal region. Of 176 patients treated with valproic acid, 80 normalized on EEG and 30 more showed EEG improvement compared with the first EEG (average of 10.1 months to repeat EEG).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403678     DOI: 10.1016/j.yebeh.2005.11.001

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  58 in total

1.  Clinical and laboratory data in a sample of Greek children with autism spectrum disorders.

Authors:  Athina Ververi; Efthymia Vargiami; Vassiliki Papadopoulou; Dimitrios Tryfonas; Dimitrios I Zafeiriou
Journal:  J Autism Dev Disord       Date:  2012-07

Review 2.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 3.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Use of transcranial magnetic stimulation in autism spectrum disorders.

Authors:  Lindsay M Oberman; Alexander Rotenberg; Alvaro Pascual-Leone
Journal:  J Autism Dev Disord       Date:  2015-02

Review 5.  Drug discovery for autism spectrum disorder: challenges and opportunities.

Authors:  Anirvan Ghosh; Aubin Michalon; Lothar Lindemann; Paulo Fontoura; Luca Santarelli
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 6.  Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD).

Authors:  Galen Missig; Christopher J McDougle; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2019-05-06       Impact factor: 7.853

7.  The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.

Authors:  Paola Sgadò; Mark Dunleavy; Sacha Genovesi; Giovanni Provenzano; Yuri Bozzi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-09

Review 8.  Epilepsy and autism: is there a special relationship?

Authors:  Anne T Berg; Sigita Plioplys
Journal:  Epilepsy Behav       Date:  2012-02-29       Impact factor: 2.937

9.  The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms.

Authors:  Manuel F Casanova
Journal:  Med Hypotheses       Date:  2007-06-14       Impact factor: 1.538

10.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.